A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCT | Aplastic Anemia & MDS International Foundation
A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCT

Clinical Trial: NCT03912064

For more details on this clinical trial, including contact information, please see this trial’s listing on clinicaltrials.gov:
Purpose: 

In this research study, our main goal for the ipilimumab portion of the study is to determine the highest dose of ipilimumab that can be given safely in several courses and to determine what side effects are seen in patients with Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS), Myeloproliferative Neoplasms (MPN), Chronic Myelomonocytic Leukemia (CMML), or Myelofibrosis (MF).

Status: 
Recruiting
Study Date: 
Thu, 04/11/2019 to Tue, 04/26/2022
Bone Marrow Disease(s): 
  • acute myeloid leukemia (AML)
  • chronic myelomonocytic leukaemia (CMML)
  • myelodysplastic syndromes (MDS)
  • myeloproliferative neoplasms (MPN)
Intervention: 
Experimental: CD25/Treg-depleted DLI + Ipilimumab Ipilimumab is administered intravenously every 12 weeks Patients will receive a defined dose of CD25hi Treg depleted DLI intravenoudsly Interventions: Drug: Ipilimumab Biological: CD25hi Treg depleted DLI